Ratings by Morgan Stanley (Mark Purcell)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/2/2026 | AstraZeneca | AZN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/23/2025 | Novo Nordisk | NVO | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/22/2024 | AstraZeneca | AZN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/15/2024 | Novo Nordisk | NVO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/16/2024 | Novartis | NVS | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/23/2024 | Novartis | NVS | New Coverage | Equalweight (N/A) |
108.23 (113.50) |
4.87% | Details | |
| 1/23/2024 | Sanofi-Aventis | SNY | New Coverage | Equalweight (N/A) |
51.03 (45.33) |
-11.17% | Details | |
| 1/23/2024 | GlaxoSmithKline | GSK | New Coverage | Equalweight (N/A) |
39.68 (51.96) |
30.95% | Details | |
| 1/23/2024 | Novo Nordisk | NVO | New Coverage | Overweight (N/A) |
106.96 (56.04) |
-47.61% | Details | |
| 1/23/2024 | AstraZeneca | AZN | New Coverage | Overweight (N/A) |
66.54 (92.77) |
39.42% | Details | |
| 6/16/2021 | GlaxoSmithKline | GSK | Maintain | Equalweight (N/A) |
|
Details |
